Individualised vs fixed dose of oral 17β-oestradiol for induction of puberty in girls with Turner syndrome: an open-randomised parallel trial

ContextOestrogen induction of pubertal changes in Turner girls may reinforce their psychological well-being and may also optimise final height; however, oestrogen type, dose, and route are not well established.ObjectiveTo induce normal pubertal development in Turner girls and ovarian insufficiency with oral 17β-oestradiol (E2), either as individualised dose (ID) or as fixed dose (FD), and to determine whether growth is affected.DesignOpen-label randomised, parallel groups, multicentre clinical trial in 48 GH-treated Turner girls. Oral E2 was given in tablets, either as an ID of 5–15 μg/kg per day during 2 years or as a FD of 0.2 mg daily during the first year followed by 0.5 mg daily during the second year. Main outcome measures were the event of attaining a Tanner breast staging ≥4 (primary), FSH, and auxological variables (secondary).ResultsShorter median time to Tanner staging ≥ B4 in the FD group (733 days) compared with the ID group (818 days) (P=0.046). Higher proportion of girls with Tanner staging ≥ B4 (65%) in the FD group compared with the ID group (42%) (P=0.068). Bone age did not show inadequate acceleration and adult height prediction was maintained in both groups. No oestrogen-related adverse events were reported.ConclusionsTwo-year treatment with oral E2 can progressively induce normal pubertal development in Turner syndrome. Low-dose oral E2 given as a FD produces a satisfactory pubertal development not inferior to ID. Treatment was well tolerated and did not interfere with the growth-promoting effect of GH.